Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

P. P. Sordillo, C. B. Magill, R. J. Gralla, D. P. Kelsen

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)273-275
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number3
Publication statusPublished - Dec 1 1982

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this